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room visits (ER), hospitalizations (HOS) using medical claims
data, and prescription costs (Rx) using pharmacy claims data.
Analysis of covariance was used to determine differences in
health care use and expenditures, adjusting for age, gender, and
number of co-morbidities. RESULTS: There were 13,796 partici-
pants in the analysis. Baseline characteristics (age, gender, and
number of co-morbidities) were comparable in the two groups
after matching. Eighty percent of migraine participants identiﬁed
were female. Analyses involving the complete models showed
that migraineurs incurred signiﬁcantly higher expenditure than
non-migraineurs. After adjusting for age, sex and number of
co-morbidities, migraineurs had signiﬁcantly more ER visits per
year (0.7 vs. 0.2, p < 0.0001). Annual ER, HOS, and Total
expenditures were signiﬁcantly higher in the Migraine cohort
(ER: $480 vs. $125, p < 0.0001 and HOS: $980 vs. $588,
p < 0.00001 and Total: $4233 vs. $2004, p < 0.0001). CON-
CLUSION: Migraine patients utilize more health care resources
and incur higher health care expenditures. Study ﬁndings high-
light the beneﬁts to be realized by managing individuals with
migraine.
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OBJECTIVE: Medication non-adherence among patients with
chronic conditions can have both clinical and economic conse-
quences. The objective is to investigate whether non-adherence to
antiepileptic drugs (AEDs) is associated with increased morbidity
relative to adherence, as proxied by health care utilization and
costs, in a Medicaid population with epilepsy. METHODS: A
retrospective open-cohort design using state Medicaid claims
data from Florida, Iowa and New Jersey in the period of January
1997–June 2006 was employed. Patients aged 18 with 1
diagnosis of epilepsy, 1 neurologist visit, 2 AED dispensings,
and 6 months of baseline period were included. Medication
possession ratio (MPR) was used to evaluate AED adherence on
a quarterly basis with MPR 0.8 considered adherent and <0.8
non-adherent. The association of non-adherence with health
care utilization was assessed using univariate and multivariate
Poisson regressions to model frequency of hospitalizations, inpa-
tient days, emergency room (ER), and outpatient visits per
person-year of observation. Quarterly per-patient inpatient, out-
patient, ER, and pharmacy costs were calculated across non-
adherent and adherent quarters for the under-65 population and
cost differences computed. Adjusted incremental costs of non-
adherence were estimated with multivariate Tobit regression
models. RESULTS: A total of 33,658 patients met the study
inclusion criteria (28,470 under-65), together contributing
388,564 (74%) adherent and 136,550 (26%) non-adherent quar-
ters. Non-adherence was associated with signiﬁcantly higher
incidence of hospitalizations (incidence rate ratio [IRR] = 1.39,
95% conﬁdence interval [CI] = 1.37–1.41), inpatient days
(IRR = 1.76, 95% CI = 1.75–1.78), and ER visits (IRR = 1.19.
95% CI = 1.18–1.21). Non-adherence was associated with posi-
tive quarterly incremental costs related to serious outcomes,
including inpatient ($4320, 95% CI = $4077–$4564) and ER
($303, 95% CI = $273–$334) services. CONCLUSION: Non-
adherence to AEDs is relatively common and appears to be
associated with increased morbidity as represented by higher
health care utilization and costs.
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OBJECTIVE: Our study explores the relationship between
30-day and 90-day pharmacy dispensing systems and patient
medication compliance, persistency, and ﬁnancial incentive.
METHODS: Retrospective pharmacy claims data of multiple
sclerosis (MS) patients using four different medications were
extracted from a pharmacy database. Patients were followed
one year. Compliance was measured using the medication pos-
session ratio (MPR), calculated using the ISPOR method. Anni-
versary method and Kaplan-Meier survival curves were applied
to describe patients’ persistency. Associations with drop-off and
different systems were assessed using Cox regression model.
Wilcoxon-Mann-Whitney test was used to compare the mean
patient out-of-pocket and payers’ costs for two systems.
RESULTS: Study sample consisted of 29,808 eligible MS
patients predominantly female (77.01%), mean age of 48.4
years. Therapy-speciﬁc MPRs on the 30-day and the 90-day
system, respectively, were 89.39% and 93.77% with a hazard
ratio (HR) for drop-off of 1.657 for Interferon beta-1a
(Avonex), 82.72% vs. 88.92% (HR = 1.486) for Interferon
beta-1b, 81.48% vs. 88.21% (HR = 1.480) for glatiramer
acetate and 87.46% vs. 90.73% (HR = 1.606) for Interferon
beta-1a (Rebif). Overall MPR comparison between 30-day and
90-day was 85.55% vs. 90.79% (HR = 1.557). Cost per dose
for patients out-of-pocket and payers for a 30-day supply was
$70.78 and $1402.10, respectively. In contrast, a 90-day supply
was $30.59 and $1404.70, respectively. Signiﬁcance tests
showed the comparison was statistically signiﬁcant at level
0.05, except comparison between payer’s costs with a p-value
of 0.46. CONCLUSION: MS patients using 90-day have higher
MPR than patients using 30-day. The patients using 30-day are
more likely to drop off, with a 55.7% higher risk of discon-
tinuation. Results suggest that providing a 90-day supply
improves MS patients’ compliance and persistency within the
one-year study period. Patients spend less when using 90-day
system. Future study focuses on pharmacoeconomic impact of
the dispensing system, incorporating outcome variables for MS
patients’ quality of life.
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OBJECTIVE: To examine compliance rates, measured with the
medication possession ratio (MPR) and 12-month persistence
rates of patients initiating 1 of 4 immunomodulating treatments
for multiple sclerosis (MS). METHODS: The study population
consisted of patients aged 18–64 years initiating MS treatment
from January 2, 2004, to July 5, 2005. Patients were identiﬁed
from an administrative claims database (PharMetrics, Inc.,
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